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Introductory paragraph
Cannabis is the most frequently used illicit psychoactive substance worldwide 1 . Life time use has been reported among 35-40% of adults in Denmark 2 and the United States 3 . Cannabis use is increasing in the population [4] [5] [6] and among users around 9% become dependent 7 . The genetic risk component is high with heritability estimates of 51 8 -70% 9 . Here we report the first genome-wide significant risk locus for cannabis use disorder (CUD, P=9.31x10 -12 ) that replicates in an independent population (P replication =3.27x10 -3 , P metaanalysis =9.09x10 -12 ). The finding is based on a genome-wide association study (GWAS) of 2,387 cases and 48,985 controls followed by replication in 5,501 cases and 301,041 controls. The index SNP (rs56372821) is a strong eQTL for CHRNA2
and analyses of the genetic regulated gene expressions identified significant association of CHRNA2 expression in cerebellum with CUD. This indicates a potential therapeutic use in CUD of compounds with agonistic effect on the neuronal acetylcholine receptor alpha-2 subunit encoded by CHRNA2. At the polygenic level analyses revealed a significant decrease in the risk of CUD with increased load of variants associated with cognitive performance.
Main
Overall the prevalence of diagnosed CUD in the population has been estimated to 1-1.5% among Europeans 10,11 and Americans 5 . CUD is associated with a range of adverse health problems 12, 13 including risk of psychosis 14, 15 , bipolar disorder 16 , anxiety disorder 17 and cognitive impairment with more persistent use associated with greater decline 18 . Estimates of the heritability for cannabis use initiation and life-time cannabis use, with respect to the amount of variance explained by common variants (i.e. the SNP heritability), has been estimated to 0.06 19 -0.2 20 . Four GWASs related to cannabis use have been conducted without genome-wide significant findings: one study of cannabis dependence 21 and three studies of lifetime cannabis use 19, 20, 22 . In addition, two recent GWASs have reported genome-wide significant associations, albeit with negative or ambiguous replication results: a study of DSM-IV cannabis dependence criterion counts in a combined sample of 14, 754 European Americans and African Americans 23 , which reported three genome-wide significant loci associated with cannabis use severity; and a GWAS of cannabis dependence of 2,080 European cases and 6,435 controls which identified one genome-wide significant locus 24 .
Here we present results from a GWAS and subsequent replication based on analyses of the largest cohorts of diagnosed CUD reported so far. Individuals included in the discovery GWAS come from the Danish nation-wide population based cohort collected by the Lundbeck Foundation Initiative for
Integrative Psychiatric Research (iPSYCH) 25 . The iPSYCH cohort was ascertained to study six major psychiatric disorders (schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit hyperactivity disorder (ADHD), anorexia nervosa and autism spectrum disorder) and consists of 79,492 genotyped individuals. The present GWAS was based on 2,387 individuals with a diagnosis of CUD (ICD10 F12.1-12.9) and 48,985 individuals not diagnosed with CUD, all identified in the iPSYCH cohort. Data analysis was conducted using the Ricopili pipeline 26 , including stringent quality control of genotyped variants and individuals (online methods).
Information about non-genotyped markers was obtained by imputation 27,28 using the 1000 genomes phase 3 as reference panel 29 . GWAS was performed using imputed marker dosages and an additive logistic regression model with relevant principal components to correct for confounders such as population stratification, and the major psychiatric disorders studied in iPSYCH as covariates. Only markers with an imputation INFO score > 0.7, minor allele frequency (maf) > 0.01 and bi-allelic markers were retained, in total 8,971,679 genetic markers. We identified 26 genome-wide significant SNPs (P< 5x10 -8 ), located in a single locus on chromosome 8 ( Figure 1 and 2). The index SNP, rs56372821, showed an odds ratio of 0.73 (P= 9.31x10 -12 ) with respect to the minor allele A (Table 1, Figure 1 and 2).
The genome-wide significant locus on chromosome 8 was replicated in an independent European sample consisting of 5,501 cases with CUD and 301,041 population controls (deCODE cohort). The cases were diagnosed with CUD while undergoing inpatient treatment at the SAA Treatment
Centre, Vogur Hospital in Iceland (www.saa.is). We tested nine markers located in the risk locus in the Icelandic sample; the index SNP and eight correlated variants (0.2 < r 2 < 0.7) with P values less than 1x10 -6 (four genome-wide significant). All variants demonstrated consistent direction of association and the most strongly associated variant (rs56372821) in the discovery GWAS had a Pvalue of 3.27x10 -3 in the deCODE cohort. In the meta-analysis rs56372821, became slightly stronger associated with CUD (P = 9.09x10 -12 ), and additional two variants became genome-wide significant (Table 1) .
There was no evidence of association of previously identified genome-wide significant cannabis risk varaints with CUD in our analyses 23, 24 (Supplementary Table 1 ). ). This might be due to different phenotype definitions among the studies as Sherva et al. 23 analysed association with cannabis criterion counts, and Agrawal et al. 24 used cannabis exposed (but not dependent)
individuals as controls in their study. Additionally, the composition of the cohorts analysed also differ as the previous GWASs were based on cohorts established to study genetics of substance use disorders while the iPSYCH cohort is ascertained for major mental illnesses (Supplementary Table   2 ).
To assess the proportion of phenotypic variance explained by common variants we applied LD We found no signs of contributions from confounding factors like population stratification and cryptic relatedness to the inflation in the distribution of the test statistics (see quantile-quantile plot, Figure 1 .B.) using LD score regression, since the intercept was one (intercept = 0.996; SE=0.0079) (online methods).
In the GWAS we corrected for diagnoses of the major psychiatric disorders studied in iPSYCH (see Supplementary Table 2 for distribution of psychiatric disorders among CUD cases and the control group). In addition, we evaluated the impact on the odds ratio for the index SNP by leave-one-out analyses excluding psychiatric phenotypes one at a time in the association analysis (online methods). The odds ratio remained stable ( Table 2 ), supporting that the association was independent of a diagnosis with one the psychiatric disorders evaluated.
The risk locus on chromosome 8 has also been found to be genome-wide significantly associated with schizophrenia 26 . In our leave-one-phenotype out analysis the locus remained genome-wide significant when individuals with schizophrenia were removed, excluding any potential confounding from schizophrenia ( Table 2 ). The signal observed for the index SNP (rs73229090) in the GWAS meta-analysis of schizophrenia 26 is consistent with the direction of association observed in our analysis. Since individuals with schizophrenia often use cannabis (around 13% -16% 33,34 ) it could be speculated that the significant signal observed in schizophrenia, is driven by a sub-group of schizophrenia cases also having CUD. This hypothesis is supported by analysis of the association of rs56372821 with schizophrenia in the iPSYCH sample. We found a nominal significant association of the SNP with schizophrenia when including individulas with co-morbid CUD (2,281 schizophrenia cases and 23,134 controls; OR=0.9; P=0.036), while after exclusion of individuals with CUD (556 cases and 101 controls excluded) the association signal disappeared (1,727 cases, 23,033 controls; OR = 0.97, P=0.63). In order to evaluate further the impact of CUD comorbidity on the odds ratio of rs56372821 in schizophrenia a null distribution for the odds ratio was generated by performing 10,000 permutations randomly removing 556 and 101 individuals among the cases and controls, respectively (Supplementary Figure 1) . The observed odds ratio for rs56372821, when excluding individuals with comorbid CUD was 0.97, and differed significantly from random removal of the same number of cases and controls (P two-sided =0.0027, P one-sided =0.0015). Thus the permutation test supports the hypothesis that the subgroup diagnosed with CUD among schizophrenia cases drives the nominal association observed for rs56372821 in the iPSYCH schizophrenia sample.
We performed a CUD-only analysis testing all SNPs in LD with the index SNP (19 SNPs; r 2 > 0.7)
for association with age at first diagnosis. This analysis suggested the risk alleles to be associated with earlier age at first diagnosis (most significant SNP: rs35236974, P = 0.020). On average CUD cases homozygous for the protective allele got their diagnosis (mean age: 22.41; st.dev = 3.63) one year later than CUD cases having at least one risk allele (mean age: 21.01; st.dev = 3.56).
Among the brain tissues analysed in GTEx the index SNP rs56372821 was found to be a strong eQTL for CHRNA2 in cerebellum (P-value in GTEx =2.1x10 -7 ), with the risk allele (G-allele) being associated with decreased expression of the gene (Supplementary Figure 2) . In order to further evaluate the potential regulatory impact of the identified locus on chromosome 8 as well as gene expression differences between cases and controls genome-wide, we imputed the genetically regulated gene expression in 11 brain tissues using PrediXcan 35 . The SNP weights used were derived from models trained on reference transcriptome data sets including 10 brain tissues from Figure 3) . The signal was driven by opposite expression patterns in a large number of brain tissues, e.g in cerebellum where CNR1 had a relatively high expression in the cerebellar cortex and CHRNA2 had a relatively low expression and the opposite was observed for cerebellar nuclei (Supplementary Figure 3) . This suggests the existence of a currently uncharacterized biological interaction between the endocannabinoid system and alpha-2 subunit containing nAChR, by which the identified risk locus which is associated with decreased CHRNA2 expression could be related to increased CNR1 expression.
The observed association of CHRNA2 unerexpression with CUD, also implies that the alpha-2 subunit can be a potential drug target in the treatment of CUD, by the use of an agonist selective for Table 5 ).
In order to evaluate the genetic overlap between CUD and a range of other phenotypes at the polygenic level, we conducted analyses of polygenic risk scores (PRS) for 22 phenotypes related to cognition, personality, psychiatric disorders, reproduction and smoking behaviour (online methods;
list of phenotypes and results can be found in Supplementary Table 6 ). PRS for eight phenotypes Individuals with acute intoxication (diagnosis code F12.0) were not included. The F12.0 diagnosis is related to the acute pharmacological effects of cannabis use and resolve with time, and does not necessary reflect long term problematic cannabis use, which is the focus of this study. All individuals in the iPSYCH sample not having a diagnosis of CUD were used as controls and covariates for the major psychiatric disorders studied by iPSYCH were used in the analyses in order to correct for the presence of mental disorders. Only 54 individuals had a diagnosis of CUD and anorexia, and all individuals having a diagnosis of anorexia among cases and the control group were excluded. Supplementary Table 2 gives an overview of the distribution of individuals with a psychiatric disorder among the CUD cases and the control group.
Processing of samples, genotyping, QC and imputing was done in 23 waves. In this study individuals from the first four waves were excluded as only a few cannabis use disorder cases were present in these waves (range 0-15 cases). The waves represent approximate birth years and the four waves that were excluded represent to a large extend individuals, which in 2013 (the time of extraction of register diagnoses) were children.
Genotyping, quality control and GWAS
DNA was extracted from dried blood spot samples and whole genome amplified in triplicates as described previously 99, 100 105 were excluded). Genetic relatedness was estimated using PLINK v1.9 106, 107 to identify first and second-degree relatives (! > 0.2) and one individual was excluded from each related pair (cases preferred kept over controls). Genetic outliers were identified for exclusion based on principal component analyses (PCA) using EIGENSOFT 108, 109 . A genetic homogenous sample was defined based on a subsample of individuals being Danes for three generations (identified based on register information about birth country of the individuals, their parents and grandparents). The subsample of Danes was used to define the center based on the mean values of principal component (PC) 1 and PC2. Subsequently PC1 and PC2 were used to define a genetic homogenous population by excluding individuals outside an ellipsoid with axes greater than six standard deviations from the mean.
Association analysis was done using logistic regression and the imputed marker dosages. The following covariates were used: principal component 1-4 and principal components from the PCA associated with case-control status, the 19 data-processing waves and diagnosis of major psychiatric disorders studied by iPSYCH (supplementary Table 2 ). Results for 9,729,295 markers were generated, subsequently markers with imputation info score < 0.7 (n = 608.367), markers with maf < 0.01 (n=10.220) and multi-allelic markers (n = 143,083) were removed. In total after filtering 8,969,939 markers remained for further analysis. All analyses of the iPSYCH sample were performed at the secured national GenomeDK high performance-computing cluster in Denmark (https://genome.au.dk).
Replication
The genome-wide significant locus on chromosome 8 was replicated in an independent European cohort consisting of 5,501 cases with diagnosed CUD and 301,041 population controls collected by deCODE genetics. The characteristics of the SAA treatment sample have been described previously 110 and currently diagnoses at Vogur Hospital are made using DSM-V, but most of the diagnoses in this study are based on DSM-IV or DSM-IIIR. The genotypes were obtained based on SNP array data and whole genome sequences using long range phasing and two types of imputations 111 . For the replication study, markers were looked up in the results of a genome-wide association study performed by logistic regression treating disease status as the response and genotype counts as covariates. Other available individual characteristics that correlate with disease status were also included in the model as nuisance variables, using previously described methods 112 .
The resulting P values were corrected for inflation by the method of genomic controls (correction factor=1.42). Nine genetic variants all representing the same association signal on chromosome 8
with P values less than 1x10 -6 were looked up in the deCODE results. The variants in the locus were selected based on LD (0.2 < r 2 < 0.7). We included additional markers besides the index SNP in order to be able evaluate the consistency of direction of association in the replication cohort over a set of markers located in the associated risk locus. The data were meta-analyzed using summary statistics and inverse variance weighted fixed effects model, implemented in the software METAL 113 . All tested variants demonstrated consistent direction of association in the replication cohort.
Heritability
SNP heritability (h 2 SNP ) was estimated by LD score regression 30 using summary statistics from the GWAS of CUD and pre-computed LD scores (available on https://github.com/bulik/ldsc). The SNP heritability was calculated on the liability scale using a prevalence of 1% in the population. The 
Leave-one phenotype out GWAS
In the GWAS of CUD we corrected, by covariates, for five major psychiatric disorders analysed in iPSYCH (Supplementary Table 2 ). However, in order to further evaluate the potential impact on the association signal of the index SNP from the psychiatric phenotypes, sensitivity analyses were performed where one phenotype at a time was excluded from the association analysis. The phenotypes evaluated were schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit hyper activity disorder, autism and individuals not having any of the five diagnoses. GWASs were performed as previously described excluding one of the six phenotypes one at a time (sample size for number of cases and controls is shown in Table 2 ).
Permutation based evaluation of the odds ratio of rs56372821 for schizophrenia with and without CUD
We applied a permutation based approach in order to evaluate how the inclusion and exclusion of individuals with CUD affected the association of our index SNP rs56372821 with schizophrenia.
The analyses were based on the iPSYCH sample consisting of 2,281 schizophrenia cases and 23,134 population based controls (genotyping, QC and imputation were done using the same procedures as explained above). Odds ratios were obtained by the glm() function in R using dosage data from the imputed SNP rs56372821, and including principle components PC1-PC4 + PCs signicantly associated with SZ and/or CUD and wave number as covariates.
In the association analysis of schizophrenia the odds ratio of 56372821(CI95%) was OR=0. of the same number of schizophrina cases and controls (P two-sided =0.0027), producing a significant increase of OR rs56372821 compared to random removal (P one-sided =0.0015).
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Association with age at first diagnosis
In order to test for a potential impact of the risk locus on age at first diagnosis, a case only study was performed testing for association of the index SNP (rs56372821) and SNPs in LD with this (r 2 > 0.7; 19 variants) with age at first diagnosis. Date of diagnosis was identified from register information in the Danish Psychiatric Central Research Register 95 . Analysis for association with age at first diagnosis (natural logarithm (age at first diagnosis)) was done using linear regression and the same covariates as used in the GWAS (PCs, wave and the psychiatric disorders). A dominant model with respect to the risk allele, was applied.
PrediXcan
The genetically regulated gene expression was imputed in 11 brain tissues using PrediXcan
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(models downloaded from: https://github.com/hakyimlab/PrediXcan; version 6 data). PrediXcan was used to impute the transcriptome for cases and the control group using SNP weights derived from models trained on reference transcriptome data sets including 10 brain tissues from GTEx (https://www.gtexportal.org/home/) and transcriptome data from dorsolateral prefrontal cortex generated by the CommonMind Consortium 37,(Huckins et al. submitted to Nature Genetics) . The models were trained on 1000 genome SNPs and contained only gene expression prediction models with a false discovery rate less than 5%. Gene expression levels in the iPSYCH data were imputed wave-wise and subseqeuntly the imputed data were merged. We tested for association of 2,459 -10,930
protein coding genes (depending on the tissue; see Supplementary Table 3) , with CUD using logistic regression corrected by the relevant principal components from PCA and the psychiatric disorder as described for the GWAS. Since gene expression among the different brain tissues is highly correlated, evaluated based on GTEx data 114 , we corrected the P-value for each gene by the total number genes tested in all tissues with a valid model available for the gene, with respect to CHRNA2 we corrected for 13,166 genes tested in three tissues.
PRS risk score analyses
PRS analyses were done using GWAS summary statistics from 22 GWASs (Supplementary Table   6 ). The summary files were downloaded from public databases and processed using the munge script which is a part of the LDscore regression software 30 . All variants with INFO < 0.9, MAF < 0.01, missing values, out of bounds P-values, ambiguous strand alleles and duplicated rs-ids were removed using the munge script. In addition, mult-allelic variants and insertion and deletion (indels)
were removed. The processed summary files were then LD-clumped using Plink, with the following parameter settings: --clump-p1 1 --clump-p2 1 --clump-r2 0.1 --clump-kb 500. The clumped file were used as the training dataset. Genetic risk scores were estimated at different P-value thresholds for SNP inclusion: 5x10 -8 , 1x10 -6 , 1x10 -4 , 1x10 -3 , 0.01, 0.05, 0.1, 0.2, 0.5 and 1.0 for all individuals in the target sample (CUD cases and the control group) from the genotype dosages using Plink's '--score' method, with default arguments. However the PRS scores for ADHD, were generated using the approach described Demontis et al. 90 . For each P-value threshold the variance in the phenotype explained by PRS was estimated using Nagelkerke's R (R package 'BaylorEdPsych') 2 , and association of PRS with CUD was estimated using logistic regression including the same covariates used in the GWAS analysis (PCs from PCA and the psychiatric disorders listed in Supplementary We are grateful to the following researchers for providing the results for the replication: Thorgeir E. The iPSYCH project is funded by the Lundbeck Foundation (grant numbers R102-A9118 and R155-2014-1724) and the universities and university hospitals of Aarhus and Copenhagen. Genotyping of iPSYCH samples was supported by grants from the Lundbeck Foundation, the Stanley Foundation, the Simons Foundation (SFARI 311789 to MJD), and NIMH (5U01MH094432-02 to MJD). The Danish National Biobank resource was supported by the Novo Nordisk Foundation. Data handling and analysis on the GenomeDK HPC facility was supported by NIMH (1U01MH109514-01 to Michael O'Donovan and ADB). High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB).
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Anders D. Børglum, anders@biomed.au.dk Ditte Demontis, ditte@biomed.au.dk Table 1 . Genome-wide significant SNPs associated with cannabis use disorder Results for genome-wide significant SNPs in the associated locus at chromosome 8 in the primary GWAS and/or in the meta-analysis with results from an independent cohort collected by deCODE. Results for the index SNP (Index SNP) is shown together with results from supporting correlated SNPs in the locus (0.2 < r 2 < 0.7) (LD SNPs). Alleles for the variants (A1 and A2), frequency of A1 in controls (Frq A1 con), the odds ratio (OR) for the effect of A1, and P-values (P) are given. Table 2 . The effect on the odds ratio of rs56372821 of leave-one-phenotype out association analysis
In the analyses individuals with a psychiatric diagnosis are excluded one disorder at a time (without ADHD (woADHD), without autism spectrum disorder (woASD), without bipolar disorder (woBP), without the iPSYCH control cohort (woCON), without major depressive disorder (woMDD), without schizophrenia (woSZ). The P-value for association with CUD (P-value), number of cases (cases), frequency of the minor allele in cases (Freq cases), number of controls (con), frequency of the minor allele in controls (Freq con), odds ratio (OR) and standard error (SE), are given. For illustration ln(OR), and the corresponding standard error. 
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